Lwaleed, B.A. and Bass, P.S. (2006) Tissue factor pathway inhibitor: Structure, biology and involvement in disease. Journal of Pathology, 208, (3), 327-339. (doi:10.1002/path.1871)
http://eprints.soton.ac.uk/19319/

Full text of this item is not available from this server.

Official URL: http://www3.interscience.wiley...2/ABSTRACT

Abstract

Tissue factor (TF)-initiated coagulation plays a significant role in the pathophysiology of many diseases, including cancer and inflammation. Tissue factor pathway inhibitor (TFPI) is a plasma Kunitz-type serine protease inhibitor, which modulates initiations of coagulation induced by TF. In a factor (F) Xa-dependent feedback system, TFPI binds directly and inhibits the TF-FVII/FVIIa complex. Normally, TFPI exists in plasma both as a full-length molecule and as variably carboxy-terminal truncated forms. TFPI also circulates in complex with plasma lipoproteins. The levels and the dual inhibitor effect of TFPI on FXa and TF-FVII/FVIIa complex offers insight into the mechanisms of various pathological conditions triggered by TF. The use of selective pharmacological inhibitors has become an indispensable tool in experimental haemostasis and thrombosis research. In vivo administration of recombinant TFPI (rTFPI) in an experimental animal model prevents thrombosis (and re-thrombosis after thrombolysis), reduces mortality from E. coli-induced-septic shock, prevents fibrin deposition on subendothelial human matrix and protects against disseminated intravascular coagulation (DIC). Thus, TFPI may play an important role in modulating TF-induced thrombogenesis and it may also provide a unique therapeutic approach for prophylaxis and/or treatment of various diseases. In this review, we consider structural and biochemical aspects of the TFPI molecule and detail its inhibitory mechanisms and therapeutic implications in various disease conditions.

Edit this item (Staff only)

References in Article

Broze GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolys 1995; 6: 7-13.
Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343.
Girard TJ, Warren LA, Novonty WF, Likert KM, Brown SG, Miletich JB, Broze GJ Jr. Functional significance of the Kuntiz-type inhibitor domains of the lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-520.
Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26 950-26 955.
Lindhout T, Franssen JO, Willems G. Kinetics of the inhibitor of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-915.
Hamik A, Setiadi H, Bu G, McEver RP, Morrissey JH. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 4962-4969.
Han X, Girard TJ, Baum P, Abendschein DR, Broze GJ Jr. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler Thromb Vasc Biol 1999; 19: 2563-2567.
Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-972.
Lwaleed BA, Bass PS, Francis JL. Urinary tissue factor: a potential marker of disease. J Pathol 1999; 188: 3-8.
Lwaleed BA, Bass PS, Cooper AJ. The biology and tumour-related properties of monocyte tissue factor. J Pathol 2001; 193: 3-12.
Lwaleed BA. Tissue factor: biological function and clinical significance. Saudi Med J 2002; 23: 135-143.
Thomas L. Studies on the intravascular thromboplastin effect of tissue suspensions in mice: II. A factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component. Bull Johns Hopkins Hosp 1947; 81: 26-42.
Schneider CL. The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. Am J Physiol 1947; 149: 123-129.
Biggs R, MacFarlane RG. The reaction of hemophiliac plasma to thromboplastin. J Clin Invest 1951; 4: 445-449.
Hjort PF. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957; 9: 1-182.
Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labelled factor IX and factor X in human plasma. Blood 1984; 63: 1338-1347.
Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985; 66: 204-212.
Broze GJ Jr, Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci USA 1987; 84: 1886-1890.
Wun TC, Kretzmer KK, Girard JT, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kuntize-type inhibitor domains. J Biol Chem 1988; 263: 6001-6004.
Valentin S, Ostergaard P, Kristensen H, Nordfang O. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays. Blood Coagul Fibrinolys 1991; 2: 629-635.
Harenberg J, Malsch R, Heene DL. Tissue factor pathway inhibitor: proposed heparin recognition region. Blood Coagul Fibrinolys 1995; 6: 50-56.
Sandset PM, Abildgaard U. Extrinsic pathway inhibitor - the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-239.
Bognacki J, Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinolys 1995; 6: 65-72.
Girard TJ, Eddy R, Wesselschmidt RL, MacPhail LA, Likert KM, Byers MG, et al. Structure of the human lipoprotein-associated coagulation inhibitor gene. J Biol Chem 1991; 266: 5036-5041.
Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18 832-18 937.
Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546.
Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ, Schwartz AL. The carboxy-terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cell in vitro and in vivo. J Clin Invest 1995; 95: 1773-1781.
Day CD, Hoffman LC, Palmier MO, Kertzmer KK, Huang MD, Pyla EY, et al. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue factor thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 76: 1538-1545.
Holst J, Lindblad B, Bergqvist D, Nordfang O, Ostergaard PB, Petersen JL, et al. Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model. Haemostasis 1993; 23: 112-117.
Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolys 1992; 3: 439-449.
Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolys 1994; 5: 441-559.
Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
Ostergaard P, Nordfang O, Petersen LC, Valentin S, Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations. Haemostasis 1993; 23: 107-111.
Kristensen HI, Ostergaard P, Nordfang O, Abildgaard U. Effect of tissue factor pathway inhibitors in the HEPTEST and in the anti-Xa amidolytic assay for LMW heparin. Thromb Haemost 1992; 68: 310-314.
Abildgaard U, Sandset PM, Lindahl AK. Tissue factor pathway inhibitor. In Recent Advances in Blood Coagulation, Poller L (ed.). Churchill Livingstone: Edinburgh, 1993; 105-124.
Jeske K, Hoppensteadt D, Fareed J, Bermes E. Measurements of functional and immunologic levels of tissue factor pathway inhibitor. Some methodological considerations. Blood Coagul Fibrinolys 1995; 6: 73-80.
Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada-Shiba M, Koh H, et al. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cells-associated forms of TFPI. Arterioscler Thromb 1996; 16: 802-808.
Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: are they different? Can J Cardiol 1998; 14: 28-34.
Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant tissues. Thromb Haemost 1993; 69: 366-369.
Sandset PM. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 1996; 26: 154-165.
Erlich JH, Apostolopoulos J, Wun TC, Kretzmer KK, Holdsworth SR, Tipping PG. Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits. J Clin Invest 1996; 98: 325-335.
Palmier MO, Hall LJ, Reisch CM, Baldwin MK, Wilson AG, Wun TC. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992; 68: 33-36.
Lwaleed BA, Greenfield RS, Birch BR, Cooper AJ. Does human semen contain a functional haemostatic system? A possible role for tissue factor pathway inhibitor in fertility through semen liquefaction. Thromb Haemost 2005; 93: 847-852.
Hansen JB, Grimsgaard S, Huseby N, Sandset PM, Bonaa KH. Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men. Thromb Res 2001; 102: 3-13.
Hansen JB, Huseby NE, Sandset PM, Sevensson B, Lyngmo V, Nordoy A. Tissue-factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-229.
Huseby KR, Hansen JB, Huseby NE, Nordoy A. The anticoagulant potential of tissue factor pathway inhibitor (TFPI) is restricted to its free form in human plasma (Abstract). Thromb Haemost 1995; 73: 1260.
Morishita E, Hashimoto T, Asakura H, Saito M, Yamazaki M, Aoshima K, et al. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease. Thromb Haemost 1998; 79: 919-923.
Hansen JB, Huseby KR, Huseby NE, Ezban M, Nordoy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res 1997; 85: 413-425.
Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL. Tissue factor pathway inhibitor binds to platelet thrombospondin-1. J Biol Chem 2000; 275: 31 715-31 721.
Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003; 1: 1495-1503.
Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10: 502-509.
Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor-1. Blood 2005; 105: 2384-2391.
Wiiger MT, Prydz H. The epidermal growth factor receptor (EGFR) and proline-rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells. Thromb Haemost 2004; 92: 13-22.
Zhang J, Piro O, Lu L, Broze GJ Jr. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108: 623-627.
Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LV, Ruf W. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20: 874-882.
Zitoun D, Bara L, Samama MM. Compared activity of human, rat and rabbit plasma tissue factor pathway inhibitors. Thromb Res 1993; 72: 269-274.
Enjyoji K, Emi M, Mukai T, Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem (Tokyo) 1992; 111: 681-687.
Wesselschmidt RL, Girard TJ, Broze GJ Jr. cDNA sequence of rabbit lipoprotein-associated coagulation inhibitor. Nucleic Acids Res 1990; 18: 6440.
Kamei S, Kamikubo Y, Hamuro T, Fujimoto H, Ishihara M, Yonemura H, et al. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. J Biochem (Tokyo) 1994; 115: 708-714.
Abumiya T, Nakamura S, Takenaka A, Takenaka O, Yoshikuni Y, Miyamoto S, et al. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in carb-eating monkeys. Arterioscler Thromb 1994; 14: 483-488.
Chang JY, Monroe DM, Oliver JA, Liles DK, Roberts HR. Cloning, expression, and characterization of mouse tissue factor pathway inhibitor (TFPI). Thromb Haemost 1998; 79: 306-309.
Francischetti IM, Valenzuela JG, Andersen JF, Mather TN, Ribeiro JM. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 2002; 99: 3602-3612.
Francischetti IM, Mather TN, Ribeiro JM. Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis. Thromb Haemost 2004; 91: 886-898.
Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-1878.
Adams MJ, Oostryck R. A comparative study of functional assays for tissue factor pathway inhibitor using normal plasma and clinical samples. Blood Coagul Fibrinolys 2000; 11: 327-333.
Lindahl AK, Hammer AKG, Boffa MC. Thrombomodulin and extrinsic pathway inhibitor in plasma are increased in pancreatic carcinoma, but by different mechanisms [abstr]. Thromb Haemost 1991; 65: 950.
Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and hemophilia plasma. Thromb Haemost 1991; 66: 464-467.
Dahm AE, Andersen TO, Rosendaal F, Sandset PM. A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost 2005; 3: 651-658.
Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-393.
Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae: regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997; 17: 2964-2974.
Ott I, Neumann FJ, Kenngott S, Gawaz M, Schomig A. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. Am J Cardiol 1998; 82: 938-942.
Kopp CW, Holzenbein T, Steiner S, Marculescu R, Bergmeister H, Seidinger D, et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity. Blood 2004; 103: 1653-1661.
Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20: 1362-1373.
Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-2262.
Zhong R, Huang RB, Song SJ. Role of tissue factor pathway inhibitor-2 in ovarian tumor migration and invasion. Ai Zheng 2003; 22: 1038-1041.
Chand HS, Du X, Ma D, Inzunza HD, Kamei S, Foster D, et al. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004; 103: 1069-1077.
Tsuji R, Tatsumi N, Hino M, Nishioka T, Takubo T. Tissue factor pathway inhibitor as a universal anticoagulant for use in clinical laboratory tests. Tohoku J Exp Med 2001; 194: 165-174.
Nishioka T, Yokota M, Hino M, Tsuda I, Tatsumi N. Tissue factor pathway inhibitor can interact with platelets. J Immunol Methods 2002; 266: 181-184.
Higuchi DA, Wun TC, Likert KM, Broze GJ Jr. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 1712-1719.
Petersen LC, Bjorn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992; 67: 537-541.
Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolys 1991; 2: 425-433.
Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T, Kato M, et al. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis 2001; 154: 203-212.
Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995; 15: 879-885.
Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolys 1991; 2: 713-721.
Lorena M, Perolini S, Casazza F, Milani M, Cimminiello C. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. Thromb Res 1997; 87: 397-403.
Makris P, Hatzizacharias A, Zilidis A, Tsoukala C, Votteas VE. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. Drugs Exp Clin Res 2004; 30: 125-132.
Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-8873.
Sandset PM, Hogevold HE, Lybert T, Andersson TR, Abildgaard U. Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thromb Haemost 1989; 62: 856-860.
Larsen LF, Jespersen J, Marckmann P. Are olive oil diets antithrombotic? Diets enriched with olive, rapeseed, or sunflower oil affect postprandial factor VII differently. Am J Clin Nutr 1999; 70: 976-982.
Warr TA, Warn-Cramer BJ, Rao LV, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. Blood 1989; 74: 201-206.
Silveira A, Karpe F, Blomback M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-69.
Pérez-Jiménez F, Castro P, Lopez-Miranda J, Paz-Rojas E, Blanco A, Lopez-Segura F, et al. Circulating levels of endothelial function are modulated by dietary mono-unsaturated fat. Atherosclerosis 1999; 145: 351-358.
Sakkinen PA, Cushman M, Psaty BM, Kuller LH, Bajaj SP, Sabharwal AK, et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 1998; 80: 134-139.
Ariëns RA, Coppola R, Potenza I, Mannucci PM. The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. Blood Coagul Fibrinolys 1995; 6: 433-437.
Koh KK, Ahn JY, Kim DS, Han SH, Shin MS, Ryu WS, et al. Effect of hormone replacement therapy on tissue factor activity, C-reactive protein, and the tissue factor pathway inhibitor. Am J Cardiol 2003; 91: 371-373.
Hansen JB, Olsen JO, Osterud B. Physical exercise enhances plasma levels of extrinsic pathway inhibitor (EPI). Thromb Haemost 1990; 64: 124-126.
Matetzky S, Tani S, Kangavari S, Dimayuga P, Yano J, Xu H, et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 2000; 102: 602-604.
Barua RS, Ambrose JA, Saha DC, Eales-Reynolds LJ. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation 2002; 106: 905-908.
Ott I, Malcouvier V, Schomig A, Neumann FJ. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 2002; 105: 279-281.
Nordoy A, Bonaa KH, Sandset PM, Hansen JB, Nilsen H. Relationship between apolipoprotein E polymorphism, postprandial hyperlipaemia and hemostatic variables in patients with combined hyperlipaemia. Nutr Metab Cardiovasc Dis 2000; 10: 15-23.
Fuster V. Present concepts of coronary atherosclerosis-thrombosis, therapeutic implications and perspectives. Arch Mal Coeur Vaiss 1997; 90: 41-47.
Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-1787.
Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998; 79: 495-499.
Freeburn JC, Wallace JM, Strain JJ, Sinnamon DG, Craig BM, Johnson D, Gilmore WS. Monocyte tissue factor-like activity in post myocardial infarction patients. Br J Haematol 1998; 102: 605-608.
Llobet D, Falkon L, Mateo J, Vallve C, Martinez E, Fontcuberta J, Borrell M. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia. Thromb Res 1995; 80: 413-418.
Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-4392.
Ariëns RA, Alberio G, Moia M, Mannucci PM. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999; 81: 203-207.
Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariëns RA. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113: 537-543.
Tardy-Poncet B, Tardy B, Mismetti P, Laporte-Simitsidis S, Guyotat D, Decousus H. Heparin releasable tissue factor pathway inhibitor in young patients with venous thrombosis [abstr]. Thromb Haemost 1999; 82: 2372.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-927.
Tardy-Poncet B, Tardy B, Laporte S, Mismetti P, Amiral J, Piot M, et al. Poor anticoagulant response to tissue factor pathway inhibitor in patients with venous thrombosis. J Thromb Haemost 2003; 1: 507-510.
Kleesiek K, Schmidt M, Gotting C, Schwenz B, Lange S, Muller-Berghaus G, et al. The 536C T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
Miyata T, Sakata T, Kumeda K, Uchida K, Tsushima M, Fujimura H, et al. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb Haemost 1998; 80: 345-346.
Arnaud E, Moatti D, Emmerich J, Aiach M, de Prost D. No link between the TFPI V264M mutation and venous thromboembolic disease. Thromb Haemost 1999; 82: 159-160.
van't Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG. Increased tissue factor-initiated prothrombin activation as a result of the Arg506 Gln mutation in factor VLEIDEN. J Biol Chem 1997; 272: 20 721-20 729.
Van Dreden P, Grosley M, Cost H. Total and free levels of tissue factor pathway inhibitor: a risk factor in patients with factor V Leiden? Blood Coagul Fibrinolys 1999; 10: 115-116.
Eitzman DT, Westrick RJ, Bi X, Manning SL, Wilkinson JE, Broze GJ, Ginsburg D. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002; 105: 2139-2142.
Bombeli T, Piccapietra B, Boersma J, Fehr J. Decreased anticoagulant response to tissue factor pathway inhibitor in patients with venous thromboembolism and otherwise no evidence of hereditary or acquired thrombophilia. Thromb Haemost 2004; 91: 80-86.
Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, Tipping PG. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 1999; 60: 175-180.
Høibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial. Thromb Haemost 2001; 85: 775-781.
Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 1997; 78: 467-470.
Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 52: 165-170.
Abumiya T, Yamaguchi T, Terasaki T, Kokawa T, Kairo K, Kato H. Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 1995; 74: 1050-1054.
Suzuki M, Kudo A, Kitakami A, Doi M, Kubo N, Kuroda K, Ogawa A. Local hypercoagulative activity precedes hyperfibrinolytic activity in the subdural space during development of chronic subdural haematoma from subdural effusion. Acta Neurochir (Wien) 1998; 140: 261-265.
Hollister RD, Kisiel W, Hyman BT. Immunohistochemical localization of tissue factor pathway inhibitor-1 (TFPI-1), a kunitz proteinase inhibitor, in Alzheimer's disease. Brain Res 1996; 728: 13-19.
Ostermann H, van de Loo J. Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis 1986; 16: 386-416.
Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, Mariani G. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67: 643-654.
Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabet Care 2002; 25: 1340-1345.
Matsuda T, Morishita E, Jokaji H, Asakura H, Saito M, Yoshida T, Takemoto K. Mechanism on disorders of coagulation and fibrinolysis in diabetes. Diabetes 1996; 45: 109-110.
Vambergue A, Rugeri L, Gaveriaux V, Devos P, Martin A, Fermon C, et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 2001; 101: 367-375.
Zumbach M, Hofmann M, Borcea V, Luther T, Kotzsch M, Muller M, et al. Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus. Exp Clin Endocrinol Diabetes 1997; 105: 206-212.
Yokoyama H, Myrup B, Rossing P, Ostergaard PB. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. Diabet Care 1996; 19: 441-445.
Rao AK, Chouhan V, Chen X, Sun L, Boden G. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999; 48: 1156-1161.
Abildgaard U. Relative roles of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coagul Fibrinolys 1995; 6: 45-49.
Hedner U, Ljundberg J, Lund-Hansen T. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Blood Coagul Fibrinolys 1990; 1: 145-151.
Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O. Blocking of tissue factor inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coag Fibrinolys 1995; 6: 388-394.
Hoppensteadt DA, Jeske W, Fareed J, Bermes Jr EW. The role of tissue factor pathway inhibitor in the mediations of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolys 1995; 6: 56-64.
Lindahl AK, Boffa MC, Abildgaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost 1993; 69: 112-114.
Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990; 59: 651-656.
Miyagi Y, Koshikawa N, Yasumitsu H, Miyagi E, Hirahara F, Aoki I, et al. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem (Tokyo) 1994; 116: 939-942.
Kakkar AK, Chinswangwatanakul V, Tebbutt S, Lemoine NR, Williamson RC. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 1998; 28: 1-6.
Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1883-1889.
Berrettini M, Malaspina M, Parise P, Lucarelli G, Kisiel W, Nenci GG. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum. Am J Clin Pathol 1995; 103: 391-395.
Kawaguchi A, Miyao Y, Noguchi T, Nonogi H, Yamagishi M, Miyatake K, et al. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol 2000; 20: 251-258.
Oksuzoglu G, Simsek H, Haznedaroglu IC, Kirazli S. Tissue factor pathway inhibitor concentrations in cirrhotic patients with and without portal vein thrombosis. Am J Gastroenterol 1997; 92: 303-306.
Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. J Intern Med 1989; 225: 311-316.
Cunningham MA, Ono T, Hewitson TD, Tipping PG, Becker GJ, Holdsworth SR. Tissue factor pathway inhibitor expression in human crescentic glomerulonephritis. Kidney Int 1999; 55: 1311-1318.
Lwaleed BA. Is tissue factor a mediator of fibrin deposition in glomerular pathology? Nephrol Dial Transpl 1999; 14: 2533.
Spokas EG, Wun TC. Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. J Pharmacol Toxicol Methods 1992; 27: 225-232.
Rapp JH, Pan XM, Ghermay A, Gazetas P, Brady SE, Reilly LM. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model. J Vasc Surg 1997; 25: 726-729.
Khouri RK, Koudsi B, Kaiding F, Ornberg RL, Wun TC. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plast Surg 1993; 30: 398-402.
Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-949.
Riesbeck K, Dorling A, Kemball-Cook G, McVey JH, Jones M, Tuddenham EG, Lechler RI. Human tissue factor pathway inhibitor fused to CD4 binds both FXa and TF/FVIIa at the cell surface. Thromb Haemost 1997; 78: 1488-1494.
Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-477.
de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.
Kataoka H, Uchino H, Asada Y, Hatakeyama K, Nabeshima K, Sumiyoshi A, Koono M. Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver. Int J Cancer 1997; 72: 878-884.
Lorenzet R, Donati MB. Blood clotting activation, angiogenesis and tumor metastasis: any role for TFPI? Thromb Haemost 2002; 87: 928-929.
Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2860.
Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock. Circ Shock 1994; 44: 126-137.
Goldfarb RD, Glock D, Johnson K, Creasey AA, Carr C, McCarthy RJ, et al. Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock 1998; 10: 258-264.
Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul Fibrinolys 1993; 4: 699-706.
Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87: 930-936.
Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002; 28: 29-38.